PT1701722E - Sal do ácido n-hidroxi-4-{5-[4-(5-isopropil-2-metil-1,3-tiazol- 4-il)fenoxi]pentoxi}benzamidina-2-metanossulfónico - Google Patents

Sal do ácido n-hidroxi-4-{5-[4-(5-isopropil-2-metil-1,3-tiazol- 4-il)fenoxi]pentoxi}benzamidina-2-metanossulfónico Download PDF

Info

Publication number
PT1701722E
PT1701722E PT05817697T PT05817697T PT1701722E PT 1701722 E PT1701722 E PT 1701722E PT 05817697 T PT05817697 T PT 05817697T PT 05817697 T PT05817697 T PT 05817697T PT 1701722 E PT1701722 E PT 1701722E
Authority
PT
Portugal
Prior art keywords
benzamidine
pentoxy
thiazol
phenoxy
isopropyl
Prior art date
Application number
PT05817697T
Other languages
English (en)
Inventor
Jei Man Ryu
Jin Soo Lee
Dong Hyuk Shin
Seung Kyoo Seong
Soon Ki Cho
Chan Seok Jeon
Young Goo Jin
Ki Young Lee
Se Hyun Jung
Eun Hee Cho
Seok Hoon Ahn
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1701722(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of PT1701722E publication Critical patent/PT1701722E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
PT05817697T 2004-11-23 2005-11-22 Sal do ácido n-hidroxi-4-{5-[4-(5-isopropil-2-metil-1,3-tiazol- 4-il)fenoxi]pentoxi}benzamidina-2-metanossulfónico PT1701722E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20040096390 2004-11-23

Publications (1)

Publication Number Publication Date
PT1701722E true PT1701722E (pt) 2009-12-10

Family

ID=36498212

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05817697T PT1701722E (pt) 2004-11-23 2005-11-22 Sal do ácido n-hidroxi-4-{5-[4-(5-isopropil-2-metil-1,3-tiazol- 4-il)fenoxi]pentoxi}benzamidina-2-metanossulfónico

Country Status (19)

Country Link
US (2) US20090176846A1 (pt)
EP (2) EP1814593A4 (pt)
JP (2) JP4774053B2 (pt)
KR (2) KR100716389B1 (pt)
CN (3) CN1905871B (pt)
AT (1) ATE445397T1 (pt)
AU (2) AU2005307994B2 (pt)
BR (2) BRPI0517396A (pt)
CA (2) CA2585003C (pt)
DE (1) DE602005017118D1 (pt)
DK (1) DK1701722T3 (pt)
ES (1) ES2333739T3 (pt)
HK (1) HK1094530A1 (pt)
IL (2) IL180985A (pt)
NZ (1) NZ555725A (pt)
PT (1) PT1701722E (pt)
RU (1) RU2361867C2 (pt)
WO (2) WO2006057507A1 (pt)
ZA (2) ZA200700485B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572898C (en) * 2004-07-05 2010-04-20 Dong Wha Pharmaceutical Ind. Co., Ltd. Composition for the prevention and treatment of allergic inflammatory disease
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
RU2361867C2 (ru) * 2004-11-23 2009-07-20 Донг Вха Фармасьютикал. Инд. Ко., Лтд. Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина
US8039635B2 (en) 2007-04-19 2011-10-18 Dong Wha Pharmaceutical Co., Ltd. N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN107530342A (zh) 2015-04-28 2018-01-02 安斯泰来制药有限公司 口服给药用医药组合物
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
CN111698992A (zh) * 2017-08-18 2020-09-22 艾伯维公司 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
WO1989006959A1 (en) * 1988-02-03 1989-08-10 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
PA8441701A1 (es) * 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CN1572882A (zh) * 1999-10-28 2005-02-02 三共株式会社 苯甲脒衍生物
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
EP1490024B1 (en) * 2002-03-06 2012-01-18 EffRx Pharmaceuticals SA Effervescent compositions comprising alendronate
WO2003087061A1 (en) * 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
WO2003101431A1 (en) 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
CN100342860C (zh) * 2003-03-18 2007-10-17 兴和株式会社 抗酸剂组合物
RU2361867C2 (ru) * 2004-11-23 2009-07-20 Донг Вха Фармасьютикал. Инд. Ко., Лтд. Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина

Also Published As

Publication number Publication date
KR100716389B1 (ko) 2007-05-11
IL182647A0 (en) 2007-07-24
DK1701722T3 (da) 2010-01-11
CN100574756C (zh) 2009-12-30
CA2585003A1 (en) 2006-06-01
CN1905871B (zh) 2010-07-07
KR20060057511A (ko) 2006-05-26
DE602005017118D1 (de) 2009-11-26
WO2006057501A1 (en) 2006-06-01
IL180985A0 (en) 2007-07-04
ATE445397T1 (de) 2009-10-15
CN101693029B (zh) 2011-11-02
ES2333739T3 (es) 2010-02-26
AU2005307994A1 (en) 2006-06-01
JP4773456B2 (ja) 2011-09-14
KR101047042B1 (ko) 2011-07-06
AU2005300239A1 (en) 2006-07-06
EP1701722B1 (en) 2009-10-14
BRPI0514386B8 (pt) 2021-05-25
HK1094530A1 (en) 2007-04-04
KR20060057514A (ko) 2006-05-26
US20070254930A1 (en) 2007-11-01
BRPI0514386B1 (pt) 2021-02-09
BRPI0517396A (pt) 2008-10-14
BRPI0514386A (pt) 2008-06-10
JP4774053B2 (ja) 2011-09-14
CA2552766A1 (en) 2006-06-01
AU2005300239B2 (en) 2009-08-06
CA2585003C (en) 2010-08-17
RU2007123614A (ru) 2008-12-27
NZ555725A (en) 2008-07-31
ZA200704236B (en) 2008-11-26
WO2006057507A1 (en) 2006-06-01
IL180985A (en) 2012-02-29
IL182647A (en) 2011-04-28
ZA200700485B (en) 2007-11-28
CN101056658A (zh) 2007-10-17
EP1814593A4 (en) 2012-09-05
AU2005307994B2 (en) 2009-07-23
CA2552766C (en) 2010-08-17
JP2008520655A (ja) 2008-06-19
EP1701722A4 (en) 2007-05-16
RU2361867C2 (ru) 2009-07-20
CN1905871A (zh) 2007-01-31
EP1701722A1 (en) 2006-09-20
EP1814593A1 (en) 2007-08-08
JP2008508264A (ja) 2008-03-21
US20090176846A1 (en) 2009-07-09
CN101693029A (zh) 2010-04-14

Similar Documents

Publication Publication Date Title
EP1701722A4 (en) N-HYDROXY-4-5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2 METHANESULFONIC ACID SALT
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
WO2008090066A3 (en) Stabilization of uv-sensitive active ingredients
PE20070351A1 (es) N-[2-[haloalcoxi)fenil]heteroarilcarboxamidas fungicidas
WO2008104847A3 (en) Processes for the preparation of pramipexole and salts thereof
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
MX2009010491A (es) Derivado heterociclico de 5 miembros y su uso para propositos medicos.
UA92354C2 (en) Amino acid salts of rosiglitazone
EP1541570A4 (en) NEW PHYSIOLOGICALLY ACTIVE SUBSTANCE
TW200833682A (en) Pharmaceutical compounds
WO2006003471A3 (en) Process for the preparation of pramipexole by chiral chromatography
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2011021214A3 (en) Improved process for preparing (s)-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)benzothiazole and its dhtydrochloride monohydrate
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
WO2008133128A1 (ja) 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
NZ598754A (en) Therapeutic agent for anxiety disorders
WO2011109675A3 (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
WO2005012273A3 (en) Process for the preparation of substituted thiazoles
EP2146974A4 (en) SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT
WO2005021542A3 (en) Process for the preparation of pioglitazone
WO2006021654A8 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
NZ592930A (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
TW200730173A (en) Pharmaceutical composition enhancing production of adiponectin
WO2008010089A3 (en) Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof